ATE408688T1 - Polypeptide zur modulierung des überlebens von zellen - Google Patents

Polypeptide zur modulierung des überlebens von zellen

Info

Publication number
ATE408688T1
ATE408688T1 AT99953434T AT99953434T ATE408688T1 AT E408688 T1 ATE408688 T1 AT E408688T1 AT 99953434 T AT99953434 T AT 99953434T AT 99953434 T AT99953434 T AT 99953434T AT E408688 T1 ATE408688 T1 AT E408688T1
Authority
AT
Austria
Prior art keywords
death
p75ntr
cell survival
present
well
Prior art date
Application number
AT99953434T
Other languages
English (en)
Inventor
Perry Bartlett
Elizabeth Coulson
Katrina Fieldew
Manuel Baca
Trevor Kilpatrick
Cheema Surindar
Original Assignee
Univ Queensland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPP6353A external-priority patent/AUPP635398A0/en
Priority claimed from AUPP6351A external-priority patent/AUPP635198A0/en
Priority claimed from AUPQ0701A external-priority patent/AUPQ070199A0/en
Application filed by Univ Queensland filed Critical Univ Queensland
Application granted granted Critical
Publication of ATE408688T1 publication Critical patent/ATE408688T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT99953434T 1998-10-06 1999-10-05 Polypeptide zur modulierung des überlebens von zellen ATE408688T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPP6353A AUPP635398A0 (en) 1998-10-06 1998-10-06 A method of modulating cell survival and reagents useful for same
AUPP6351A AUPP635198A0 (en) 1998-10-07 1998-10-07 A method of modulating cell survival and reagents useful for same-ii
AUPQ0701A AUPQ070199A0 (en) 1999-06-01 1999-06-01 A method of modulating cell survival and reagents useful for same-iii

Publications (1)

Publication Number Publication Date
ATE408688T1 true ATE408688T1 (de) 2008-10-15

Family

ID=27158107

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99953434T ATE408688T1 (de) 1998-10-06 1999-10-05 Polypeptide zur modulierung des überlebens von zellen

Country Status (6)

Country Link
US (3) US20020137188A1 (de)
EP (1) EP1121434B1 (de)
AT (1) ATE408688T1 (de)
CA (1) CA2345379C (de)
DE (1) DE69939593D1 (de)
WO (1) WO2000020578A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE408688T1 (de) 1998-10-06 2008-10-15 Univ Queensland Polypeptide zur modulierung des überlebens von zellen
US6472176B2 (en) * 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
WO2003013604A2 (en) * 2001-08-09 2003-02-20 Genset S.A. Migenix agonists and antagonists for use in the treatment of metabolic disorders
AUPS230702A0 (en) * 2002-05-14 2002-06-13 Walter And Eliza Hall Institute Of Medical Research, The A method of treatment
AU2003222681B8 (en) * 2002-05-14 2009-06-18 The University Of Queensland A method of treatment
WO2006005740A2 (en) * 2004-07-14 2006-01-19 Janssen Pharmaceutica N.V. P75ntr screening assay for indentifying modulators of apoptosis
US20150344535A1 (en) * 2012-09-28 2015-12-03 The University Of Queensland Neurotrophin-tyrosine kinase receptor signaling
WO2017053506A1 (en) * 2015-09-22 2017-03-30 The Johns Hopkins University P75ntr antagonists and treatment of acute and chronic cardiac disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5606023A (en) * 1994-05-24 1997-02-25 Thomas Jefferson University Mutant tumor necrosis factor proteins
DE69626829T2 (de) * 1995-08-04 2004-03-18 Lek Farmacevtska Druzba D.D. Monoklonale antikörper gegen lösliche tnf-alpha rezeptoren p55 und p75 als auch gegen tnf-alpha und dessen analogen
ATE408688T1 (de) 1998-10-06 2008-10-15 Univ Queensland Polypeptide zur modulierung des überlebens von zellen
AU772811B2 (en) 1998-10-06 2004-05-06 University Of Queensland, The A method of modulating cell survival and reagents useful for same

Also Published As

Publication number Publication date
US7919471B2 (en) 2011-04-05
US20020137188A1 (en) 2002-09-26
WO2000020578A1 (en) 2000-04-13
US20110172143A1 (en) 2011-07-14
CA2345379A1 (en) 2000-04-13
EP1121434A4 (de) 2005-03-02
US8299027B2 (en) 2012-10-30
EP1121434A1 (de) 2001-08-08
US20050090442A1 (en) 2005-04-28
EP1121434B1 (de) 2008-09-17
DE69939593D1 (de) 2008-10-30
CA2345379C (en) 2011-12-06

Similar Documents

Publication Publication Date Title
DK0888452T3 (da) Human CYR61, et ekstracellulært matrix-signalmolekyle
ATE318905T1 (de) Homologe des tie-rezeptortyrosinekinase liganden
DK1129190T3 (da) Human TSLP DNA og polypeptider
ATE227739T1 (de) Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
NO990086D0 (no) Avkortete, oppl÷selige tumornekrosefaktorreseptorer av type I og type II
BG100771A (en) Hematopoeic protein and ways and methods for its preparation
DK1265914T3 (da) WNT-1-relaterede polypeptider og nukleinsyrer, der koder for samme
DK0970213T3 (da) Dödsdomæneholdig receptor
AU6250098A (en) Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l)
IL195337A0 (en) Cyr61 compositions and methods
ATE408688T1 (de) Polypeptide zur modulierung des überlebens von zellen
ATE311443T1 (de) Methoden zur durchforstung (screenen) von proteinen
DE69938451D1 (de) Fas peptide und antikörper zur modulierung von apoptosis
EP1282722A4 (de) Stabilisierte proteine
DE69726884D1 (de) Menschliches sdf-5 protein und diesbezügliche zusammensetzungen
ATE259652T1 (de) Neuronale verwendungen des bmp-11
ATE307826T1 (de) Oligomere von konformationsbeschränkten, nicht- peptidischen di- oder tripeptid-mimetika, und ihre verwendung zur synthese von künstlichen polypeptiden und proteinen
ATE464320T1 (de) Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
DK0804577T3 (da) cDNA, der koder en BMP type II receptor
ATE240349T1 (de) Peptide zur inhibierung von hpv e6-proteinen
CY1105226T1 (el) Dna και πολυπεπτιδια il-1 εψιλον ανθρωπου
WO1999031233A8 (en) Polypeptides, polynucleotides and uses thereof
EP1187842A4 (de) Der tr10 rezeptor des menschlichen tumor-nekrose-faktors
SE0002364D0 (sv) Growth Factors
WO2003074675A3 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties
REN Ceased due to non-payment of the annual fee